NeuroMetrix, Inc. announced expansion of its sales force to drive further adoption of Quell(R) Fibromyalgia, which is the first and only medical device authorized by the U.S. Food and Drug Administration (FDA) to help reduce the symptoms of fibromyalgia. This expansion follows positive results from the strategic launch of Quell Fibromyalgia in December 2022, and is designed to intensify commercial efforts in the California, Texas and Florida markets. Quell Fibromyalgia Indications: Quell Fibromyalgia is a transcutaneous electrical nerve stimulation (TENS) device indicated as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity.

The device may be used during sleep. Limitations The sale, distribution, and use of Quell Fibromyalgia is restricted to prescription use in accordance with 21 CFR 8801.109. The Product labeling should be reviewed for a complete list of contraindications, precautions and warnings.